Continued Maintenance With Obinutuzumab Plus Acalabrutinib/V

The undetectable minimal residual disease ate achieved with bendamustine followed by obinutuzumab, acalabrutinib, and venetoclax increased as the regimen was continued as maintenance treatment in patients with relapsed or refractory chronic lymphocytic leukemia.

Related Keywords

Germany , Paula Cramer , Abbvie Inc , Novartis , International Workshop , Astrazeneca , Novo Nordisk , International Workshop For Chronic Lymphocytic Leukemia , Glaxosmithkline , University Of Cologne , Bristol Myers Squibb , Chronic Lymphocytic Leukemia , Cumulative Illness Rating Scale , Btk Inhibitor , Cll , Leukemia , Btk Inhibitor Resistance , International Workshop On Cll , Iwcll , Mutations , Alterations , The Phase 2 Cll2 Baag Study Nct03787264 ,